Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor

The article investigates the value of canagliflozin in the management of type 2 diabetes mellitus from the perspective of a clinically-based patient-centred approach. It focusses on the outcomes of a 52-week double-blind, active-controlled study. The results of this clinical trial demonstrate that c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nina A. Petunina, Anna L. Terekhova, Ekaterina V. Goncharova
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2016
Materias:
Acceso en línea:https://doaj.org/article/fb4b48718f144cf18d9defcf7341b996
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The article investigates the value of canagliflozin in the management of type 2 diabetes mellitus from the perspective of a clinically-based patient-centred approach. It focusses on the outcomes of a 52-week double-blind, active-controlled study. The results of this clinical trial demonstrate that canagliflozin, which provides significant weight loss ability, improves the quality of life and satisfaction with physical and emotional health in patients with diabetes compared with sitagliptin.